BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De Smedt R, Morscio J, Goossens S, Van Vlierberghe P. Targeting steroid resistance in T-cell acute lymphoblastic leukemia. Blood Rev 2019;38:100591. [PMID: 31353059 DOI: 10.1016/j.blre.2019.100591] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Zhang J, Zeng L, Wang Y, Pan J, Li X, Feng B, Yang Q. Gene Mutations Related to Glucocorticoid Resistance in Pediatric Acute Lymphoblastic Leukemia. Front Pediatr 2022;10:831229. [DOI: 10.3389/fped.2022.831229] [Reference Citation Analysis]
2 Zhou Y, Guan L, Li W, Jia R, Jia L, Zhang Y, Wen X, Meng S, Ma D, Zhang N, Ji M, Liu Y, Ji C. DT7 peptide-modified lecithin nanoparticles co-loaded with γ-secretase inhibitor and dexamethasone efficiently inhibit T-cell acute lymphoblastic leukemia and reduce gastrointestinal toxicity. Cancer Lett 2022;533:215608. [PMID: 35240234 DOI: 10.1016/j.canlet.2022.215608] [Reference Citation Analysis]
3 El-Khazragy N, Abdel Aziz MA, Hesham M, Matbouly S, Mostafa SA, Bakkar A, Abouelnile M, Noufal Y, Mahran NA, Abd Elkhalek MA, Abdelmaksoud MF. Upregulation of leukemia-induced non-coding activator RNA (LUNAR1) predicts poor outcome in pediatric T-acute lymphoblastic leukemia. Immunobiology 2021;226:152149. [PMID: 34735923 DOI: 10.1016/j.imbio.2021.152149] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Bardelli V, Arniani S, Pierini V, Di Giacomo D, Pierini T, Gorello P, Mecucci C, La Starza R. T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness. Genes (Basel) 2021;12:1118. [PMID: 34440292 DOI: 10.3390/genes12081118] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
5 Cortes JR, Patrone CC, Quinn SA, Gu Y, Sanchez-Martin M, Mackey A, Cooke AJ, Shih BB, Laurent AP, Trager MH, Ferrando AA, Geskin LJ, Palomero T. Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma. J Invest Dermatol 2021:S0022-202X(21)01308-7. [PMID: 34089720 DOI: 10.1016/j.jid.2021.04.023] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
6 Maćkowska N, Drobna-Śledzińska M, Witt M, Dawidowska M. DNA Methylation in T-Cell Acute Lymphoblastic Leukemia: In Search for Clinical and Biological Meaning. Int J Mol Sci 2021;22:1388. [PMID: 33573325 DOI: 10.3390/ijms22031388] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Prescott K, Jacobs M, Stock W, Wynne J. New Approaches to Treating Challenging Subtypes of ALL in AYA Patients. Curr Hematol Malig Rep 2020;15:424-35. [PMID: 32920736 DOI: 10.1007/s11899-020-00597-y] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Laukkanen S, Oksa L, Nikkilä A, Lahnalampi M, Parikka M, Seki M, Takita J, Degerman S, de Bock CE, Heinäniemi M, Lohi O. SIX6 is a TAL1-regulated transcription factor in T-ALL and associated with inferior outcome. Leuk Lymphoma 2020;61:3089-100. [PMID: 32835548 DOI: 10.1080/10428194.2020.1804560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Xu W, Chen S, Wang X, Tanaka S, Onda K, Sugiyama K, Yamada H, Hirano T. Molecular mechanisms and therapeutic implications of tetrandrine and cepharanthine in T cell acute lymphoblastic leukemia and autoimmune diseases. Pharmacol Ther 2021;217:107659. [PMID: 32800789 DOI: 10.1016/j.pharmthera.2020.107659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
10 Xu W, Chen S, Wang X, Wu H, Yamada H, Hirano T. Methylprednisolone potentiates tetrandrine pharmacodynamics against human T lymphoblastoid leukemia MOLT-4 cells via regulation of NF-κB activation and cell cycle transition. Steroids 2020;163:108714. [PMID: 32818521 DOI: 10.1016/j.steroids.2020.108714] [Reference Citation Analysis]
11 Xu W, Wang X, Chen S, Wu H, Tanaka S, Onda K, Sugiyama K, Yamada H, Hirano T. Tetrandrine enhances glucocorticoid receptor translocation possibly via inhibition of P-glycoprotein in daunorubicin-resistant human T lymphoblastoid leukemia cells. Eur J Pharmacol 2020;881:173232. [PMID: 32525004 DOI: 10.1016/j.ejphar.2020.173232] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
12 Drobna M, Szarzyńska B, Jaksik R, Sędek Ł, Kuchmiy A, Taghon T, Van Vlierberghe P, Szczepański T, Witt M, Dawidowska M. hsa-miR-20b-5p and hsa-miR-363-3p Affect Expression of PTEN and BIM Tumor Suppressor Genes and Modulate Survival of T-ALL Cells In Vitro. Cells 2020;9:E1137. [PMID: 32380791 DOI: 10.3390/cells9051137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
13 Teachey DT, O'Connor D. How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children. Blood 2020;135:159-66. [PMID: 31738819 DOI: 10.1182/blood.2019001557] [Cited by in Crossref: 22] [Cited by in F6Publishing: 34] [Article Influence: 11.0] [Reference Citation Analysis]
14 Morscio J, Van Vlierberghe P. Chemotherapy at the wheel of ALL relapse. Blood 2020;135:4-5. [PMID: 31895951 DOI: 10.1182/blood.2019003870] [Reference Citation Analysis]